DXR

Daxor Corporation 10-K Summary (Fiscal Year Ended Dec 31, 2001)

Business Context and Reporting Period

Daxor Corporation is a medical device manufacturer and biotech service provider reporting for the fiscal year ended December 31, 2001. The Company's primary focus is the BVA-100 Blood Volume Analyzer, an FDA-cleared instrument for rapid blood volume measurement, alongside subsidiary operations in blood banking and semen banking (Idant Laboratories). The Company operates with approximately 30 employees and maintains facilities in New York, Tennessee, and Rochester (leased space not renewed in 2001).

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability: The Company reported a net income of $299,355 in 2001, marking the first profitable year in six years, compared to a net loss of $55,194 in 2000.
• Revenue Composition: Total revenue increased slightly by 2.7%. However, operating revenues from core business activities (blood/semen banking and BVA-100 sales) declined by 7% to $591,692. The increase in total revenue was driven by higher dividend income and gains on the sale of investments.
• Liquidity: Cash and cash equivalents increased significantly from $18,439 to $431,949. Short-term debt was reduced by approximately $775,000 as margin debt to brokers was paid off, leaving only a $1,000,000 bank loan secured by securities.
• Investment Portfolio: The market value of the securities portfolio decreased by approximately $6.45 million (from $48.7M to $42.3M), though it still represents the vast majority of the Company's assets.

Guidance, Outlook, and Risks

Outlook: Management intends to focus major marketing efforts on the BVA-100 Blood Volume Analyzer, anticipating it will become the primary revenue source. The Company aims to increase operating revenues even if it initially results in lower profits. They are consolidating manufacturing in Oak Ridge, Tennessee, and utilizing an Original Equipment Manufacturer (OEM) to achieve economies of scale.

Risks and Contingencies:

• Revenue Dependency: The Company relies heavily on investment income (dividends and capital gains) to offset operating expenses. Operating revenues remain low relative to total assets.
• Market Acceptance: Success depends on demonstrating the cost-effectiveness and accuracy of the BVA-100 to hospitals and HMOs. The Company faces the challenge of changing medical practices regarding blood volume measurement.
• Regulatory: Operations are subject to FDA regulation for medical devices and New York State Department of Health regulation for blood and semen banking.
• Unrealized Gains: A significant portion of Shareholders' Equity ($13.85 million) consists of net unrealized holding gains on available-for-sale securities, which are subject to market volatility.

Investor Verification Checklist

• Operating Revenue Trend: Verify the decline in core operating revenue ($591k) versus the reliance on investment income ($1.86M) to determine the sustainability of the recent profitability.
• Investment Portfolio Valuation: Confirm the fair value of the $42.3M securities portfolio and the impact of potential market downturns on the Company's liquidity and equity.
• BVA-100 Adoption: Assess the actual sales volume and lease agreements for the BVA-100 to validate management's claim that it will become the primary revenue driver.
• Debt Covenants: Review the terms of the $1,000,000 bank loan secured by marketable securities to understand potential margin call risks if the portfolio value declines.
• Reimbursement Status: Verify current Medicare and insurance reimbursement rates for blood volume testing to ensure the economic model for hospitals remains viable.